Agilent Technologies (A) investor relations material

Market opportunity and growth outlook

• Outsourced oligonucleotide manufacturing market projected to grow from $2B in 2026 to over $4B by 2030, with a 15% CAGR driven by RNA-based oligos, especially siRNA.

• siRNA represents a rapidly expanding niche, with more than double the number of active programs in the last five years and future therapies targeting larger patient populations.

• Company has achieved 6X revenue growth in oligo manufacturing over the past decade, reflecting strong market leadership.

Capabilities, infrastructure, and customer positioning

• Operates state-of-the-art GMP facilities in Colorado and Canada, with expanded capacity through a $740M investment since 2023 to meet rising demand.

• Integrated clinical-to-commercial platform with a proven regulatory track record, supporting most commercial siRNA programs globally.

• Embedded in seven approved global commercial therapies, with market authorizations in over 30 countries and hundreds of successful audits.

Technology and manufacturing evolution

• Solid-phase synthesis remains the industry standard for siRNA API production, with enzymatic ligation and de novo synthesis emerging for larger scale and higher purity.

• Company is positioned to evolve with technology trends, maintaining validated methods while investing in next-generation manufacturing processes.

• Expanded infrastructure includes purpose-built facilities for both siRNA/antisense and guide RNA manufacturing, improving sustainability and scalability.